Clinical Trial Update: An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating subcutaneous zilucoplan in generalized myasthenia gravis patients previously treated with IV C5 inhibitors; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Zilucoplan (zilucoplan)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2025-03-30